KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Amneal Pharmaceuticals (AMRX) Shares Outstanding (Weighted Average): 2016-2024

Historic Shares Outstanding (Weighted Average) for Amneal Pharmaceuticals (AMRX) over the last 9 years, with Dec 2024 value amounting to $309.8 million.

  • Amneal Pharmaceuticals' Shares Outstanding (Weighted Average) rose 1.47% to $314.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was $314.1 million, marking a year-over-year increase of 1.47%. This contributed to the annual value of $309.8 million for FY2024, which is 1.08% up from last year.
  • Per Amneal Pharmaceuticals' latest filing, its Shares Outstanding (Weighted Average) stood at $309.8 million for FY2024, which was up 1.08% from $306.5 million recorded in FY2023.
  • In the past 5 years, Amneal Pharmaceuticals' Shares Outstanding (Weighted Average) ranged from a high of $309.8 million in FY2024 and a low of $299.7 million during FY2020.
  • Its 3-year average for Shares Outstanding (Weighted Average) is $306.7 million, with a median of $306.5 million in 2023.
  • Data for Amneal Pharmaceuticals' Shares Outstanding (Weighted Average) shows a peak YoY grew of 1.08% (in 2024) over the last 5 years.
  • Amneal Pharmaceuticals' Shares Outstanding (Weighted Average) (Yearly) stood at $299.7 million in 2020, then rose by 0.58% to $301.5 million in 2021, then increased by 0.70% to $303.6 million in 2022, then rose by 0.97% to $306.5 million in 2023, then rose by 1.08% to $309.8 million in 2024.